Marsh (MRSH) Stock Price & How to Invest

Marsh (ticker MRSH, formerly Marsh & McLennan Companies under MMC) is a global professional services firm built around two segments. Risk and Insurance Services houses Marsh, the world's largest insurance brokerage, and Guy Carpenter, a leading reinsurance broker. The Consulting segment houses Mercer, a large health, wealth, and career consultancy, and Oliver Wyman, a management consulting brand. Together these businesses employ roughly 90,000 people and generate the bulk of revenue from recurring commissions and advisory fees tied to commercial insurance placement, reinsurance, retirement, and workforce advisory work.

The investment picture is that of a defensive, fee-driven compounder. Revenue is diversified across geographies and end markets, insurance broking benefits from multi-year commercial pricing cycles, and the consulting arm adds exposure to retirement, benefits, and strategy demand. The company has a long track record of mid-single-digit to high-single-digit organic growth, steady margin expansion, consistent buybacks, and decades of dividend increases. The trade-off is a premium valuation and sensitivity to the commercial insurance rate cycle, so the stock tends to behave like a quality holding rather than a rapid grower.

As an insurance broker, revenue is tied to the commercial insurance pricing cycle, and a prolonged soft market with falling premium rates would slow commission growth. The consulting businesses are more cyclical and can weaken when corporate clients cut discretionary project and benefits spending. The stock trades at a premium valuation (a low-20s price to earnings multiple), so disappointing organic growth or margins could compress the multiple. Large acquisitions carry integration and goodwill risk, and the firm faces professional liability and regulatory exposure across many jurisdictions. Currency swings also affect reported results given the global footprint.

21 analysts publish price targets on MRSH, averaging $205.52 against a $189.69 price as of August 2026, or +8.3%. The published targets run from $180.00 to $238.00, a narrow spread, and the ratings split 7 buy, 15 hold, 1 sell. Over the last six months there have been 7 raises and 4 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MRSH forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Marsh. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Insurance brokerage scale and pricing cycle. Marsh is the largest insurance broker globally, and its commissions rise with commercial insurance premium rates. The most optimistic published target, $238.00, assumes this works close to its best case.

The case against. As an insurance broker, revenue is tied to the commercial insurance pricing cycle, and a prolonged soft market with falling premium rates would slow commission growth. The most pessimistic target, $180.00, is roughly what MRSH is worth if this bites instead.

Read the full bull and bear case on MRSH, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Marsh's investor relations page or your broker.

• Revenue (TTM): ~$27.5B
• Net income (TTM): ~$4.2B
• Diluted EPS (TTM): ~$7.99
• Market cap: ~$86B
• P/E (TTM): ~22x
• Dividend yield: ~2.1%

Marsh generated roughly $27 billion in trailing revenue with high-single-digit organic growth and expanding adjusted margins. It trades around a low-20s price to earnings multiple, a premium that reflects its recurring fee revenue and steady compounding rather than rapid growth. The next quarterly report is expected in late July 2026.

Other names that sit close to MRSH: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MRSH exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MRSH sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MRSH fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

MRSH is a blue-chip insurance and advisory franchise whose appeal rests on recurring fee revenue, pricing power, and a long dividend record rather than rapid growth.

Whether MRSH is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MRSH a buy or a sell?, and where the stock could go from here in the MRSH stock forecast.

For income investors, whether MRSH pays a dividend and how the payout looks is covered in does MRSH pay a dividend? And to weigh MRSH against a peer, read the full side-by-side comparisons: MRSH vs AJG and MRSH vs WTW.